从肠促胰素分泌机制看胰升糖素样肽1在2型糖尿病治疗中的应用

被引：6

作者：

李小英

机构：

[1] 上海交通大学医学院附属瑞金医院内分泌代谢病科,上海市内分泌代谢病研究所,上海市内分泌代谢病临床医学中心

来源：

中华内分泌代谢杂志 | 2011年 / 04期

关键词：

糖尿病,2型; 肠促胰素; 胰升糖素样肽1;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

摘要：

近年来在2型糖尿病发病机制及治疗领域研究中,肠促胰素是一大突破。本文以肠促胰素分泌生理机制、病理变化到临床应用为线索,简要介绍了营养物质(葡萄糖、脂肪和蛋白质)触发肠促胰素分泌机制、2型糖尿病患者肠促胰素分泌障碍以及一种重要的肠促胰素——胰升糖素样肽1在2型糖尿病治疗中的应用。

引用

页码：365 / 368

共 11 条

[1] Secretion of glucagon-like peptide-1 （GLP-1） in type 2 diabetes: what is up, what is down?[J] . M. A. Nauck,I. Vardarli,C. F. Deacon,J. J. Holst,J. J. Meier.Diabetologia . 2011 (1)
[2] Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial[J] . The Lancet . 2010 (9724)
[3] Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors[J] . Jaime A. Davidson.Mayo Clinic Proceedings . 2010 (12)
[4] Pleiotropic Actions of the Incretin Hormones[J] . Christopher H.S. McIntosh,Scott Widenmaier,Su-Jin Kim.Vitamins and Hormones . 2010
[5] Nutritional regulation of glucagon-like peptide-1 secretion
Tolhurst, Gwen
Reimann, Frank
Gribble, Fiona M.
[J]. JOURNAL OF PHYSIOLOGY-LONDON, 2009, 587 (01): : 27 - 32
[6] Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
Parker, H. E.
Habib, A. M.
Rogers, G. J.
Gribble, F. M.
Reimann, F.
[J]. DIABETOLOGIA, 2009, 52 (02) : 289 - 298
[7] Biology of Incretins: GLP-1 and GIP[J] . Laurie L. Baggio,Daniel J. Drucker.Gastroenterology . 2007 (6)
[8] Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes[J] . Gary A. Herman,Arthur Bergman,Catherine Stevens,Paul Kotey,Bingming Yi,Peng Zhao,Bruno Dietrich,George Golor,Andreas Schrodter,Bart Keymeulen,Kenneth C. Lasseter,Mark S. Kipnes,Karen Snyder,Deborah Hilliard,Michael Tanen,Caroline Cilissen,Marina De Smet,Inge de Lepeleire,Kristien Van Dyck,Amy Q. Wang,Wei Z
[9] Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes[J] . A Mari,W M. Sallas,Y L. He,C Watson,M Ligueros-Saylan,B E. Dunning,C F. Deacon,J J. Holst,J E. Foley.The Journal of Clinical Endocrinology ＆ Metabolism . 2005 (8)
[10] Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes
Lugari, R
Dei Cas, A
Ugolotti, D
Finardi, L
Barilli, AL
Ognibene, C
Luciani, A
Zandomeneghi, R
Gnudi, A
[J]. HORMONE AND METABOLIC RESEARCH, 2002, 34 (03) : 150 - 154

← 1 2 →